Source: U.S. Food and Drug Administration From: PR Newswire The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer. For patients with this type of cancer, Nerlynx is the first extended adjuvant therapy, a form of therapy that is taken after an initial treatment to further lower the risk of …
EU Recommends Approval of Roche’s Pre-Surgery Breast Cancer Treatment
From: dddmag.com Roche announced that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approves the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for the neoadjuvant treatment (use before surgery) of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. The EU filing was …
Breast Cancer Cocktail Buys More Than a Year of Life
By: Maggie Fox and Maren Shapiro From: nbcnews.com A cocktail of three breast cancer drugs buys patients an extra 16 months of life — a good news story so unusual, doctors have rushed to make it standard therapy, researchers said Wednesday. The combination includes two so-called magic bullet drugs plus standard chemotherapy. It helps patients with advanced HER-2 positive breast …
Aggressive breast cancer protein discovered
From: nursingtime.net “A breakthrough by scientists could lead to a new treatment for one of the most aggressive forms of breast cancer,” the Mail Online reports. Researchers have identified a protein called integrin αvβ6, which may help trigger the spread of some types of breast cancer. Up to a third of breast cancers are HER2-positive cancers. These are cases of …